KR102337130B1 - Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating obesity comprising a fermented product of oriental medicine composite materials containing Hooker chives and black garlic as an active ingredient and a method for preparing the same, and a food composition for preventing or alleviating obesity comprising a fermented product of oriental medicine composite materials containing Hooker chives and black garlic as an active ingredient and a method for preparing the same. The fermented product of the oriental medicine composite materials exerts an anti-obesity effect, and thus can be advantageously used for preventing, ameliorating or treating obesity, as well as improving immunity through anti-inflammatory activation, and maintaining body balance through activation of gastric and intestinal functions, and the product is also non-toxic as an active ingredient derived from natural products, thereby securing the stability of long-term use.

Description

A composition comprising fermented oriental medicine composite material as an active ingredient for preventing, improving or treating obesity, and a method for preparing the same

The present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a fermented product of an oriental medicine composite material containing three vegetables and black garlic as an active ingredient, a method for preparing the same, and a fermented product of an oriental medicine composite material containing three vegetables and black garlic as an active ingredient It relates to a food composition for preventing or alleviating obesity comprising A fermented product of oriental medicine composite material, including three vegetables and black garlic, which can inhibit the differentiation into ginseng and can promote the decomposition of medium fat, etc., and can be usefully used for the prevention, improvement or treatment of obesity To a pharmaceutical composition for preventing or treating obesity comprising

With the recent economic growth and changes in lifestyle, western-style eating habits have become common, and lifestyle-type diseases such as diabetes, high blood pressure, and cardiovascular disease are increasing. In particular, in the case of busy modern people, excessive weight and obesity are increasing due to a high-calorie diet such as fast food and a small amount of exercise. Overweight means a body mass index (BMI, a measure of obesity divided by weight squared) of 25 or more and less than 30, and obesity means a body mass index of 30 or more. Two-thirds of American adults are overweight or obese, and excess weight increases blood pressure and cholesterol levels, increasing the incidence of various adult diseases such as heart disease. The effect of obesity on various diseases is very serious, and it is known that obesity is the cause of 80% of diabetic patients and 21% of heart disease patients worldwide. In addition, various cancers such as uterine cancer, kidney cancer, and breast cancer are also directly or indirectly related to obesity, and in the case of obesity or overweight, the incidence of sleep apnea, osteoarthritis, and cholelithiasis is higher than that of normal people (Stein CJ, Colditz GA. The epidemic of Obesity J Clin Endocrinol Metab 2004; 89: 2522-2525; Kopelman PG Obesity as a medical problem. Nature 2000 Apr 6; 404(6778): 635-43).

In addition, according to the National Health and Nutrition Examination Survey, the obese population (those with a BMI of 25 or higher) in Korea accounted for only 14.8% of the total population in 1995, but surged to 26.2% of the total population in 2001, and 39.8% of the total population in 2019. % and it shows a continuous increase trend, the national interest in obesity prevention, improvement and treatment is rapidly increasing.

Recently, obesity has also begun to be recognized as one of the diseases, and as obesity-induced cardiovascular diseases, diabetes, arthritis, and various cancers have been proven, people around the world are recognizing the severity of obesity.

Obesity is not a disease caused by a single cause, but is difficult to treat by any one method because it is caused by a combination of several factors such as genetic, social, environmental, and mental factors. Currently, methods for treating obesity can be divided into lifestyle correction methods such as diet therapy, exercise therapy, and behavior therapy, and drug therapy and surgical therapy. Active efforts to correct lifestyle should be preceded by drug or surgical treatment, but it is not easy to correct lifestyle and there is a limit to the weight that can be reduced only by lifestyle modification. Therefore, in many cases, drug treatment is required along with lifestyle modification.

For the drug treatment of obesity, many anti-obesity agents are being developed every year. Anti-obesity drugs are i) hormone regulators that stimulate the central nervous system, ii) appetite suppressants that suppress appetite by inducing satiety through ingestion of fiber rather than energy sources such as sugar, iii) secreted by the pancreas and digestive system A lipase inhibitor that inhibits the absorption of fat in food by inhibiting lipase, iv) Adipocyte differentiation that reduces fat cells by blocking the pathway through which adipocytes are differentiated into adipocytes Inhibitors, and v) lipolysis agents that break down accumulated fat in differentiated adipocytes. is limited to In the case of agents that control digestion or appetite, they are classified as psychotropic drugs because of their habit, and digestive inhibitors exhibit side effects such as diarrhea and constipation.

The representative obesity treatment drugs approved for long-term use by the US FDA until 2010 are sibutramine (Abbott's Reductil), which inhibits the reuptake of norepinephrine and serotonin, and in the pancreas and digestive system. There is orlistat (Xenical from Roche), which exhibits an effect by inhibiting secreted lipase (Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.). However, sibutramine was withdrawn from the United States and Korea in October 2010 because side effects such as elevated blood pressure, insomnia, dry mouth, and dizziness are common, and there is a risk of cardiovascular symptoms such as myocardial infarction and stroke. In addition, orlistat has common side effects such as diarrhea, fatty stools, and loss of money, and its use is limited because the effect of the drug is not clear when the intake of fat is lower than that of Westerners such as Koreans. 1998; 7(4): 287-92.). Therefore, there is still no anti-obesity drug that has good anti-obesity effect and has been confirmed to be safe for long-term use.

Korean Patent Application Laid-Open No. 10-2016-0145323 discloses a composition for preventing and treating obesity, which includes fermented three chaes as an active ingredient. Although the composition for preventing and treating obesity contains an active ingredient derived from a natural product, the anti-obesity effect is not sufficient and thus needs to be further improved.

It is an object of the present invention, by including a fermented product of oriental medicine composite material comprising three vegetables and black garlic as an active ingredient, a pharmaceutical composition capable of preventing or treating obesity, or a food composition capable of preventing or ameliorating obesity, and a food composition thereof To provide a manufacturing method.

In order to achieve the object of the present invention, according to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity, comprising as an active ingredient a fermented product of an oriental medicine composite material containing three vegetables and black garlic.

According to another aspect of the present invention, (1) preparing a yeast culture solution; And (2) the method for producing a pharmaceutical composition for preventing or treating obesity is provided, comprising the step of fermenting by adding the oriental herbal composite material comprising three chaechae and black garlic to the yeast culture solution obtained in step (1).

According to another aspect of the present invention, there is provided a food composition for preventing or improving obesity, comprising as an active ingredient a fermented product of an oriental medicine composite material comprising three vegetables and black garlic.

According to another aspect of the present invention, (1) preparing a yeast culture solution; And (2) the method for producing a food composition for preventing or treating obesity is provided, comprising the step of adding and fermenting the oriental herbal composite material comprising three chaechae and black garlic to the yeast culture solution obtained in step (1).

The composition according to the present invention can inhibit lipase enzyme activity and inhibit the differentiation of preadipocytes into adipocytes and Since it can promote the decomposition of triglycerides, it can be usefully used as a pharmaceutical composition for preventing or treating obesity (preferably a therapeutic agent) and a food composition for preventing or improving obesity (preferably a health functional food).

In addition, the composition according to the present invention can improve immunity with an anti-obesity effect, and improve body balance through activation of gastric and intestinal functions.

In addition, since the composition according to the present invention is a composition derived from a natural product and has no toxicity, it is possible to secure the stability of long-term administration for the prevention, improvement or treatment of obesity.

The composition according to the present invention can inhibit lipase enzyme activity and inhibit the differentiation of preadipocytes into adipocytes and Since it can promote the decomposition of triglycerides, it can be usefully used as a pharmaceutical composition for preventing or treating obesity (preferably a therapeutic agent) and a food composition for preventing or improving obesity (preferably a health functional food).
In addition, the composition according to the present invention can improve immunity with an anti-obesity effect, and improve body balance through activation of gastric and intestinal functions.
In addition, since the composition according to the present invention is a composition derived from a natural product and has no toxicity, it is possible to secure the stability of long-term administration for the prevention, improvement or treatment of obesity.

The present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a fermented product of an oriental medicine composite material containing three vegetables and black garlic as an active ingredient, a manufacturing method thereof, and a fermented product of an oriental medicine composite material containing three vegetables and black garlic as an active ingredient It relates to a food composition for preventing or improving obesity, and a method for manufacturing the same.

Hereinafter, the present invention will be described in more detail.

According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity, comprising as an active ingredient a fermented product of an oriental medicine composite material comprising three vegetables and black garlic.

In one embodiment of the present invention, the oriental medicine composite material includes three vegetables and black garlic.

Samchae (三菜) has the effect of inhibiting the synthesis of cholesterol, and is a herbal ingredient that helps to improve blood circulation by lowering cholesterol levels and dissolving blood clots. In addition, the fiber content of three chae is good for preventing vascular diseases such as high blood pressure, arteriosclerosis, and hyperlipidemia, as it helps to purify and purify the blood. In addition, samchae has a high potassium content, which is effective in balancing the body by helping to discharge sodium accumulated in the body.

Samchae is also rich in calcium, so it helps in bone formation and bone health of growing children. It is rich in 'dietary sulfur', a material of collagen that composes cartilage and ligaments, to help prevent arthritis and osteoporosis. The 'dietary sulfur' contained in three vegetables is twice that of onion, six times that of garlic, and 60 times that of ginseng. Samchae is also effective in preventing gout as it helps to discharge purines, the cause of uric acid.

Samchae is especially known as a good food to prevent adult diseases. Complications such as high blood pressure or decreased visual acuity may occur if you have diabetes. Because the 'saponin' component of Samchae controls blood lipid levels and stabilizes blood sugar, it is effective in preventing or improving high blood pressure or diabetes. to be.

Samchae has effects such as preventing obesity by reducing body fat, promoting bone health, and alleviating menopausal symptoms. have.

The three-chae used in the present invention may be three-leaf, root, or flower, and the root is more preferable, but is not limited thereto.

Black garlic is produced by aging raw garlic at a temperature of 50°C to 90°C for 15 to 40 days. During the ripening period, sugars and amino acids contained in garlic react to form a browning substance, and these browning substances are collected. As it turns black, black garlic is completed. During the ripening period, some of the active ingredients of raw garlic are reduced, but the content of new active ingredients is increased.

Black garlic consists of 63% water and contains various nutrients such as vitamin C, vitamins B1 and B2, potassium and phosphorus. have. In particular, allin is the main ingredient that gives garlic its pungent taste and unique aroma. Allin itself has no flavor, but when garlic is minced or sliced, allinase in garlic works and allin is changed to allicin. Allicin has strong antibacterial and bactericidal action, inhibits the growth of harmful bacteria, reduces cholesterol, triglyceride and blood LDL levels, and increases HDL levels, thereby helping to improve hyperlipidemia and arteriosclerosis, thereby reducing the risk of cardiovascular disease. have.

In one embodiment of the present invention, the oriental medicine composite material may include additional herbal ingredients in addition to three vegetables and black garlic, and the additional oriental medicinal ingredients include green tea, dermis, angelica, turmeric, gardenia, astragalus, crust, health and these It may be one or more selected from the group consisting of a combination of. By using additional herbal ingredients in addition to samchae and black garlic, it is possible to not only improve the anti-obesity effect, but also improve immunity, and improve body balance through activation of gastric and intestinal functions.

Green tea grows in salt fields of the southwest coast or the salty soil around it, and absorbs various components in seawater or mudflats and retains good components through photosynthesis. Green tea, which sprouts in spring and grows dark green throughout the summer, and leaves its leaves after mid-September, is a treasure trove of minerals containing a large amount of minerals such as sodium 1,003mg, calcium 235mg, potassium 650mg, iron 40mg per 100g. 6 times more iron than seaweed or kelp. In addition, green tea is rich in dietary fiber and amino acids, and contains dozens of trace elements such as saponins and flavonoids. It is helpful in preventing adult diseases such as removing fat from sukbyeon and improving constipation. It also lowers cholesterol levels and is effective in discharging fat from the blood and blood vessels.

Jinpi (陳皮) is a medicinal herb made from the peel of the ripe fruit of the tangerine tree. It is a plate-shaped shell with an irregular shape and is about 2 mm thick. The outer surface is yellowish red to dark brown, and there are many small concave marks due to loss. The inside is white to light gray brown, and the quality is light and easy to break. The dermis contains 28 kinds of flavonoid-based compounds, and in addition, it contains monoterpenoid-based compounds. The pharmacological action of the dermis includes lipase activity inhibition, anti-ulcer treatment effect, blood pressure lowering effect, antiviral action, anti-inflammatory action, anti-allergic action and anticancer action.

Angelica (當歸) is a medicinal herb obtained by drying the root of Angelica Root, which softens the intestines to prevent constipation, and is also effective in skin whitening and moisturizing. Angelica is rich in various vitamins, so it is more helpful for the skin, replenishes moisture to dry and rough skin, and is effective in purulent acne, sore throat and bronchitis through its anti-inflammatory and antibacterial action. In addition, Angelica quai produces blood and promotes blood circulation, so it is effective in eliminating eohyeol and in menstrual pain and menstrual irregularities. In addition, Angelica's main component prevents platelet aggregation, keeping blood clear and not coagulated, and can improve blood circulation. Angelica quai removes harmful free radicals in the blood, prevents inflammation, and gently relaxes and expands narrowed blood vessels, so it is effective in preventing cardiovascular diseases such as arteriosclerosis, angina, and myocardial infarction.

Turmeric (鬱金) is a root crop of the ginger family, and has a bitter taste and is yellow in color in common with turmeric, a material for curry. Commonly cultivated in India is turmeric and cultivated in Korea is divided into turmeric, but there is little nutritional difference. Recently, the Ministry of Food and Drug Safety stipulates that turmeric and turmeric are the same, and the two names are used in parallel. Turmeric contains a component called curcumin. Indian turmeric has a curcumin content of 0.4 to 0.6%, whereas domestic turmeric has a curcumin content of about 1%. Turmeric can exert various effects. Turmeric can protect the heart by reducing LDL levels in the blood, aid digestion and absorption, promote toxin excretion, inhibit the formation of new blood vessels in cancer cells, and inhibit cancer cell proliferation by inducing apoptosis. In addition, turmeric can relieve chronic inflammation due to its strong anti-inflammatory action, and is excellent for inflammatory diseases such as arthritis, rheumatism, and gout. It can reduce digestive disorders by promoting blood circulation and improving the supply of nutrients and oxygen to the stomach. In addition, various physiologically active substances contained in turmeric help the body to remove free radicals, waste products and toxins.

Gardenia (梔子) is the mature fruit of the evergreen shrub belonging to the Apiaceae family. Originating from China, it was introduced to Korea from China 500 years ago. It is mainly distributed in East Asia such as Korea, Japan, China, Taiwan and India. In Korea, it grows mainly in the southern regions. In Gyeongsangnam-do and Jeollanam-do, it is grown outdoors, and in Seoul, it is planted in a pot and enjoyed. The flowers have a strong fragrance and are transmitted far away, and their flowers and fruits are beautiful, so they are suitable as ornamental trees. Gardenia has a cold and bitter taste, and acts on the meridians of the liver and heart to remove heat, release fire, and purify the blood. Gardenia is effective against fever, insomnia, antipyretic, hemostasis, nosebleeds, anti-inflammation, inflammatory diseases, hepatitis, and jaundice.

Gardenia fruit contains crocin, a carotenoid pigment, and when hydrolyzed, it becomes crocelin and glucose. Crosin and croceline of the gardenia promote bile secretion and excretion, have the effect of treating jaundice by suppressing an increase in bilirubin in the blood, and have an effect of lowering cholesterol and triglycerides to prevent arteriosclerosis.

Hwanggi (黃耆) is a perennial plant in the legume family, mainly native to Korea, Japan, China, and eastern Siberia. Astragalus is introduced as a perennial plant of leguminous species in the Chinese herbal herbal medicine book, Shennong Herbal Herbs, and in Korea's Dongui Bogam, Astragalus restores vitality and makes you gain weight, stops fever, and deafness due to weakness in the body. treatment is recorded. In Korea, Astragalus grows mainly in Jeongseon-gun, Gangwon-do, Jecheon, Chungcheongbuk-do, and Bonghwa-gun, Gyeongbuk. Astragalus contains polysaccharides, amino acids, vitamin P and trace minerals. Astragalus is good for managing digestive and respiratory diseases and has the effect of enhancing energy.

Gyeok (枳殼) refers to the dried mature yellow tangja fruit, and the dried unripe blue tangja fruit is called jisil. Both drugs have similar efficacy, but when prescribed together with other oriental herbal medicines, a relatively gentle nature is often used. The crust helps to stop coughing and asthma, and the vitamins C and potassium contained in the crust are effective in preventing colds. In particular, it has the effect of relieving lumps, so it is good for chest or stomach stuffiness, and it is effective in decomposing phlegm, so it is good to prevent sinusitis and a cold. Also, the crust strengthens the stomach, aids digestion, and stops colic. It is also effective in treating atopic dermatitis due to its anti-allergic action.

Health (乾薑) refers to dried rhizomes of ginger, a perennial herb belonging to the ginger family. Health promotes gastric juice secretion, activates intestinal peristalsis, promotes digestion, relieves vomiting, excites the heart to increase blood pressure, promotes blood circulation, and has anti-inflammatory, analgesic and antibacterial properties.

In one embodiment of the present invention, the total content of three vegetables and black garlic is 20 parts by weight or more, 21 parts by weight or more, 22 parts by weight or more, 23 parts by weight or more, 24 parts by weight or more, 25 parts by weight or more, 26 parts by weight or more, 27 parts by weight or more, 28 parts by weight or more, 29 parts by weight or more, or 30 parts by weight or more, and also 60 parts by weight or less, 58 parts by weight or less, 56 parts by weight or less, 54 parts by weight or more. parts by weight or less, 52 parts by weight or less, 50 parts by weight or less, 48 parts by weight or less, 46 parts by weight or less, 45 parts by weight or less, 44 parts by weight or less, 42 parts by weight or less, or 40 parts by weight or less.

In a preferred embodiment of the present invention, the total content of three vegetables and black garlic may be 20 to 60 parts by weight, specifically 25 to 50 parts by weight, more specifically 30 to 45 parts by weight, based on 100 parts by weight of the total oriental medicine composite material. . When the total content of the three vegetables and black garlic is less than 20 parts by weight based on 100 parts by weight of the total of the herbal composite material, the anti-obesity effect of the pharmaceutical composition for preventing or treating obesity may be lowered, and when it exceeds 60 parts by weight, As the cost rises, the economic feasibility may decrease.

In one embodiment of the present invention, the content of additional herbal ingredients other than three vegetables and black garlic is 40 parts by weight or more, 42 parts by weight or more, 44 parts by weight or more, 46 parts by weight or more, based on 100 parts by weight of the total oriental medicinal composite material. 48 parts by weight or more, 50 parts by weight or more, 52 parts by weight or more, 54 parts by weight or more, 55 parts by weight or more, 56 parts by weight or more, 58 parts by weight or more, or 60 parts by weight or more, and also 80 parts by weight or less, 79 parts by weight or more. parts by weight or less, 78 parts by weight or less, 77 parts by weight or less, 76 parts by weight or less, 75 parts by weight or less, 74 parts by weight or less, 73 parts by weight or less, 72 parts by weight or less, 71 parts by weight or less, or 70 parts by weight or less.

In a preferred embodiment of the present invention, the content of additional herbal ingredients other than three vegetables and black garlic is 40 to 80 parts by weight, specifically 50 to 75 parts by weight, more specifically 55 to 80 parts by weight, based on 100 parts by weight of the total oriental medicinal composite material. It may be 70 parts by weight. When the content of the additional oriental medicine material is less than 40 parts by weight based on 100 parts by weight of the total of the oriental medicine composite material, the effect of improving immunity and maintaining body balance may be insignificant, and when it exceeds 80 parts by weight, obesity prevention or The anti-obesity effect of the pharmaceutical composition for treatment may be insignificant.

In one embodiment of the present invention, the three vegetables, black garlic and additional herbal ingredients can be used without limitation, such as those obtained by direct cultivation or commercially available ones.

In one embodiment of the present invention, the fermented product of the oriental medicine composite material including the three vegetables and black garlic may be a fermented product of the oriental medicine composite material using a yeast culture solution.

In one embodiment of the present invention, the yeast culture medium is Aspergillus niger (Aspergillus niger), Aspergillus oryzae (Aspergillus oryzae), Saccharomyces cerevisiae (Saccharomyces cerevisiae) or a combination thereof It may be obtained by culturing a yeast strain selected from the group, preferably Aspergillus niger ( Aspergillus niger ) and Saccharomyces cerevisiae ) It may be obtained by culturing a combination of, but limited thereto doesn't happen

In one embodiment of the present invention, the pharmaceutical composition for preventing or treating obesity of the present invention may further include a fermented rice bran in addition to the fermented product of the oriental medicine composite material.

Rice, which has a long history as a food resource for mankind, is composed of the chaff layer, rice bran layer, snow and endosperm. The rice is brown rice from which the rice hull layer is removed according to the degree of milling; And by milling brown rice, it is obtained in the form of polished rice from which rice bran is removed, such as rice germ, pericarp, seed hide, and aloe layer, and includes a rice hull layer or rice germ and aloe layer, saragi, etc. By-products such as the rice bran layer are called rice bran. According to recent research results, rice bran, which was previously treated as a by-product, is reported to contain about 95% of the physiologically active substances contained in rice, such as gamma aminobutyric acid (GABA), lecithin, octacosanol, oryzanol, tocopherol, and ferulic acid. Because rice bran contains many physiologically active substances, it is known to have various physiologically active effects such as anti-obesity activity, anti-cholesterol activity, anti-hypertensive activity, hangover relieving activity, heavy metal detoxification activity and anti-constipation activity.

In one embodiment of the present invention, the fermented rice bran may be fermented rice bran using a culture medium of lactic acid bacteria.

The strain used to prepare the lactic acid bacteria culture medium is not particularly limited as long as it is a pharmaceutically acceptable lactic acid bacteria, for example, Lactobacillus casei ( Lactobacillus casei ), Lactobacillus acidophilus ( Lactobacillus acidophilus ), Lactobacillus helvetti kusu (Lactobacillus hellveticus), Lactobacillus biasing Li (Lactobacillus gasseri), Lactobacillus momentum spread (Lactobacillus fermenturm), Lactobacillus salivarius (Lactobacillus salivalius), Lactobacillus jugul Ti (Lactobacillus jugulti), Lactobacillus delbeu rwikki seopseu pisiseu. Bulgaricus ( Lactobacillus delbrueckii subsp. bulgaricus ), Lactobacillus johnsoni ( Lactobacillus Johnsonii ) Lactobacillus genus bacteria such as; Streptococcus genus bacteria, such as Streptococcus thermophilus; Lactococcus lactis subspisis. lactis ( Lactococcus lactis subsp. lactis), Lactococcus lactis subsp. Cremoris ( Lactococcus lactis subsp. cremoris ), Lactococcus plantarum ( Lactobacillus plantarum ), Lactococcus raffinolactis ( Lactococcus raffinolactis ) Lactococcus bacteria such as; Enterococcus faecalis ( Enterococcus faecalis ), Enterococcus faecium ( Enterococcus faecium ) Enterococcus genus bacteria such as; Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium rongeom (Bifidobacterium longum), Bifidobacterium Infante Tees (Bifidobacterium infantis), Bifidobacterium Adolfo Les sentiseu (Bifidobacterium adolescentis), Bifidobacterium Bifidobacterium bonus ( Bifidobacterium bifidum ), Bifidobacterium catenulatum , Bifidobacterium pseudocatenulatum ), Bifidobacterium angulatum ( Bifidobacterium angulatum ), Bifidobacterium lactis ), Bifidobacterium animalis ( Bifidobacterium animalis ) Bifidobacterium genus bacteria such as, and preferably, may be a Bifidobacterium genus bacteria. In addition, these lactic acid bacteria may be used alone or in combination of two or more.

In one embodiment of the present invention, the fermented rice bran may be used to replace all or part of conventional excipients. The fermented rice bran can not only serve as a conventional excipient, but also exhibit anti-obesity activity, etc., thereby reinforcing the anti-obesity activity of the fermented product of the oriental medicine composite material.

In one embodiment of the present invention, when the pharmaceutical composition for preventing or treating obesity of the present invention includes the fermented product of the oriental medicine composite material and the fermented rice bran together, the weight of the fermented product of the oriental medicine composite material and the fermented rice bran The ratio may be 1:1 to 5:1, preferably 3:1 to 5:1. By adjusting their weight ratio within the above range, it is possible to reduce the amount of the excipient used while greatly improving the anti-obesity effect, and to improve economic feasibility according to cost reduction.

In the present invention, it was confirmed that, when the oriental herbal composite material is fermented using a yeast culture medium, the ability to inhibit lipase enzyme activity can be significantly improved compared to before fermentation of the oriental medicine composite material. In addition, the fermented product of the oriental medicine composite material of the present invention can inhibit the production of adipocytes by inhibiting the process of adipogenesis of preadipocytes into adipocytes, and can inhibit the decomposition of triglycerides in adipocytes. can promote

As a result, the fermented product of the oriental medicine composite material inhibits the absorption of fat by inhibiting the decomposition of fat in food by lipase by inhibiting lipase enzyme activity, and inhibiting the differentiation of adipocytes into adipocytes. By inhibiting the production of adipocytes and promoting the breakdown of triglycerides in adipocytes, an excellent anti-obesity effect can be exerted.

Therefore, the fermented product of the oriental medicine composite material can be usefully used as a pharmaceutical composition for preventing or treating obesity.

The pharmaceutical composition for preventing or treating obesity of the present invention may be in various oral or parenteral formulations. When formulating the composition, it is usually prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include one or more compounds and at least one excipient, for example, starch, dextrin, calcium carbonate, sucrose, or It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, solutions, emulsions, or syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances or preservatives may be included. can

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, or suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, and the like can be used.

The pharmaceutical composition for preventing or treating obesity of the present invention may be administered orally or parenterally, and when parenteral administration is administered externally or intraperitoneally, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebrovascular injection is selected. It is preferable to do

The pharmaceutical composition for preventing or treating obesity of the present invention is administered in a pharmaceutically effective amount. In the present invention, the effective dose level depends on the patient's disease type, severity, drug activity, sensitivity to drug, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs, and other medical fields. It can be determined according to well-known factors. The pharmaceutical composition for preventing or treating obesity of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the pharmaceutical composition for preventing or treating obesity of the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of disease, and daily administration The amount is 0.01 to 1,000 mg/kg, preferably 30 to 500 mg/kg, more preferably 50 to 300 mg/kg, based on the amount of fermented material of the oriental medicine composite material, administered 1 to 6 times a day can be However, since it may increase or decrease depending on the route of administration, the severity of obesity, sex, weight, age, etc., the dosage is not intended to limit the scope of the present invention in any way.

The pharmaceutical composition for preventing or treating obesity of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

According to another aspect of the present invention, (1) preparing a yeast culture solution; And (2) there is provided a method for producing a pharmaceutical composition for preventing or treating obesity, comprising the step of fermenting by adding the oriental herbal composite material containing three chaesae and black garlic to the yeast culture solution obtained in step (1).

In one embodiment of the present invention, the yeast culture medium of step (1) is Aspergillus niger (Aspergillus niger), Aspergillus oryzae, Saccharomyces cerevisiae (Saccharomyces cerevisiae) or Yeast strains selected from the group consisting of combinations thereof, preferably Aspergillus niger ( Aspergillus niger ) and Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) Can be prepared by culturing a combination.

In one embodiment of the present invention, the description of the oriental medicine composite material comprising three vegetables and black garlic in step (2) is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention. The oriental medicinal composite material includes three vegetables and black garlic, and may optionally include additional oriental medicinal ingredients, and the additional oriental medicinal ingredients include green tea, dermis, angelica, turmeric, gardenia, astragalus, crust, health, and combinations thereof. It may be one or more selected from the group consisting of.

In one embodiment of the present invention, the fermentation in step (2) is at a temperature range of 30°C to 60°C, preferably 35°C to 50°C, for 12 hours to 48 hours, preferably 16 hours to 24 hours. It may be performed during, but is not limited to.

In one embodiment of the present invention, the fermentation of step (2) may be performed 1 to 3 times.

In one embodiment of the present invention, in the manufacturing method of the present invention, (3) concentrating the fermentation product of step (2) to obtain a fermentation concentrate, It may further comprise the step of recovering the by-product and drying it.

In one embodiment of the present invention, the fermentation product of step (2) includes a liquid phase and a solid phase, and in step (3), the liquid portion becomes a fermentation concentrate through freeze drying or vacuum drying, The solid portion may be the remaining by-products except for the fermentation concentrate among the fermentation products. The by-product may be separately recovered, dried at room temperature or hot air, and the dried by-product may be pulverized to prepare a powder.

In one embodiment of the present invention, the concentration of the fermentation concentrate in step (3) is 10 to 30 brix, preferably 15 to 25 brix, more preferably 17 to 23 brix, even more preferably 18 to 22 brix, but is not limited thereto.

In one embodiment of the present invention, in the manufacturing method of the present invention, (4) mixing the fermentation concentrate obtained in step (3) and the dry by-product with an excipient or diluent, kneading in a kneader, and kneading the dough It may further comprise the step of preparing the formulation from water.

In one embodiment of the present invention, in step (4), the fermentation broth of rice bran may be further mixed together with the fermentation concentrate, the dry by-product, and an excipient (or diluent). In this case, the ratio of the total weight of the fermentation concentrate and the dry by-product to the fermented rice bran by weight may be 1:1 to 5:1, preferably 3:1 to 5:1. By adjusting their weight ratio within the above range, it is possible to reduce the amount of the excipient used while greatly improving the anti-obesity effect, and to improve economic feasibility according to cost reduction.

Description of the excipient or diluent is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention.

In one embodiment of the present invention, the fermented rice bran may be fermented rice bran using a culture medium of lactic acid bacteria. At this time, the description of the lactic acid bacteria culture is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention.

In one embodiment of the present invention, the fermented rice bran may be prepared by a manufacturing method comprising the following steps, but is not limited thereto:

1) preparing a mixture by mixing rice bran and water;

2) preparing a gelatinized rice bran mixture by heating the mixture to gelatinize rice bran;

3) adding a lactic acid bacteria culture solution to the luxurious rice bran mixture; and

4) preparing a fermented rice bran by fermenting the luxurious rice bran mixture to which the lactic acid bacteria culture is added.

In one embodiment of the present invention, step 1) may be performed by mixing 100 to 200 parts by weight of water per 100 parts by weight of rice bran. In this case, the rice bran may be in the form of rice bran powder obtained by pulverizing the raw rice bran using a grinder, but is not limited thereto.

In one embodiment of the present invention, in the gelatinization of step 2), the mixture obtained in step 1) is subjected to a temperature condition of 100° C. to 140° C. and a pressure condition of 0.9 atm to 1.5 atm for 1 hour to 5 hours, preferably Preferably, it can be carried out by heating for 2 to 4 hours.

Step 2) is a step of gelatinizing rice bran, and “gelatinization” means that when starch, etc. is heated in water or treated with a solvent such as an alkali solution, it expands by heat and moisture and its physicochemical properties or structure is changed. It refers to a process of changing to have properties such as viscosity increase, water solubility increase or volume increase, or a phenomenon in which the whole becomes translucent and almost uniform colloidal material, also called gelatinization.

In one embodiment of the present invention, step 2) may include the step of cooling the gelatinized rice bran mixture to a temperature range of 30° C. to 50° C., preferably 35° C. to 45° C. after gelatinizing the rice bran.

In one embodiment of the present invention, in step 4), the gelatinized rice bran mixture to which the lactic acid bacteria culture is added is heated at a temperature of 30° C. to 50° C., preferably 35° C. to 45° C., for 12 hours to 48 hours, preferably may be performed by fermentation for 16 hours to 24 hours, but is not limited thereto.

In one embodiment of the present invention, the method for producing a fermented rice bran may further include 5) drying the fermented rice bran obtained in step 4) and pulverizing it to prepare a powder.

The drying step is i) natural drying at room temperature (20°C to 30°C) for 10 hours to 60 hours, ii) hot air drying at a temperature condition of 30°C to 60°C for 1 hour to 40 hours, or iii) It can be carried out by freeze-drying for 20 to 100 hours at a temperature condition of -50°C to -80°C.

According to another aspect of the present invention, there is provided a food composition for preventing or improving obesity, comprising as an active ingredient a fermented product of an oriental medicine composite material comprising three vegetables and black garlic.

In one embodiment of the present invention, the oriental herbal composite material may include additional oriental herbal ingredients in addition to three vegetables and black garlic, and the additional oriental herbal ingredients include green tea, dermis, angelica, turmeric, gardenia, astragalus, crust, health and It may be one or more selected from the group consisting of combinations thereof. By using additional herbal ingredients in addition to samchae and black garlic, it is possible to not only improve the anti-obesity effect, but also improve immunity, and improve body balance through activation of gastric and intestinal functions.

At this time, the description of the three chaejae, black garlic, additional herbal ingredients, oriental medicine composite materials and fermented products of the oriental medicine composite materials are the same as those described above in the pharmaceutical composition for preventing or treating obesity of the present invention.

In one embodiment of the present invention, the food composition for preventing or improving obesity of the present invention may further include a fermented rice bran in addition to the fermented product of the oriental medicine composite material. At this time, the description of the fermented rice bran is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention.

In one embodiment of the present invention, when the food composition for preventing or improving obesity of the present invention includes the fermented product of the oriental medicine composite material and the fermented rice bran together, the weight ratio of the fermented product of the oriental medicine composite material and the fermented rice bran This may be 1:1 to 5:1, preferably 3:1 to 5:1. By adjusting their weight ratio within the above range, it is possible to reduce the amount of the excipient used while greatly improving the anti-obesity effect, and to improve economic feasibility according to cost reduction.

In the present invention, it was confirmed that, when the oriental herbal composite material is fermented using a yeast culture medium, the ability to inhibit lipase enzyme activity can be significantly improved compared to before fermentation of the oriental medicine composite material. In addition, the fermented product of the oriental medicine composite material of the present invention can inhibit the production of adipocytes by inhibiting the process of adipogenesis of preadipocytes into adipocytes, and can inhibit the decomposition of triglycerides in adipocytes. can promote

As a result, the fermented product of the oriental medicine composite material inhibits the absorption of fat by inhibiting the decomposition of fat in food by lipase by inhibiting lipase enzyme activity, and inhibiting the differentiation of adipocytes into adipocytes. By inhibiting the production of adipocytes and promoting the breakdown of triglycerides in adipocytes, an excellent anti-obesity effect can be exerted.

Therefore, the fermented product of the oriental medicine composite material can be usefully used as a food composition for preventing or improving obesity.

Unless otherwise specified in this specification, "food" means a natural product or processed product containing one or more nutrients, and preferably means a state that can be directly eaten through a certain processing process, , examples include fruits, vegetables, dried products thereof, cut products, fruit juices, vegetable juices, mixed juices thereof or chips, noodles, livestock processed foods, aquatic processed foods, dairy products, fermented foods, legumes, grain foods. , microbial fermented food, confectionery, condiments, processed meat, acidic beverages, licorice, herbs, and the like, and is meant to include fermented food, functional food and processed food in the present invention, but is not limited thereto.

The food composition for preventing or improving obesity of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., but is not limited thereto, and may be manufactured and processed in any form according to the law.

The food composition for preventing or improving obesity of the present invention may be added to food as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of its use (for prevention or improvement). In general, the amount of the fermented product of the oriental medicine composite material in the health functional food may be added in an amount of 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

The food composition for preventing or improving obesity of the present invention is not particularly limited in other ingredients except for containing the fermented product of the oriental medicine composite material as an essential ingredient in the indicated ratio, and various flavoring agents or natural carbohydrates, etc. may be contained as an additional component. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and conventional sugars such as polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .

In addition to the above, the food composition for preventing or improving obesity of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food composition for preventing or improving obesity of the present invention may contain natural fruit juice, fruit juice, and fruit for the production of a fruit juice beverage and vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not so important, but is generally selected in the range of 0.1 to about 10 parts by weight per 100 parts by weight of the total weight of the food composition for preventing or improving obesity of the present invention.

According to another aspect of the present invention, (1) preparing a yeast culture solution; And (2) there is provided a method of producing a food composition for preventing or improving obesity, comprising the step of fermenting by adding the oriental herbal composite material containing three chaechae and black garlic to the yeast culture solution obtained in step (1).

In one embodiment of the present invention, the yeast culture medium of step (1) is Aspergillus niger (Aspergillus niger), Aspergillus oryzae, Saccharomyces cerevisiae (Saccharomyces cerevisiae) or Yeast strains selected from the group consisting of combinations thereof, preferably Aspergillus niger ( Aspergillus niger ) and Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) Can be prepared by culturing a combination.

In one embodiment of the present invention, the description of the oriental medicine composite material comprising three vegetables and black garlic in step (2) is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention. The oriental medicinal composite material includes three vegetables and black garlic, and may optionally include additional oriental medicinal ingredients, and the additional oriental medicinal ingredients include green tea, dermis, angelica, turmeric, gardenia, astragalus, crust, health, and combinations thereof. It may be one or more selected from the group consisting of. By using additional herbal ingredients in addition to samchae and black garlic, it is possible to not only improve the anti-obesity effect, but also improve immunity, and improve body balance through activation of gastric and intestinal functions.

In one embodiment of the present invention, the fermentation in step (2) is at a temperature range of 30°C to 60°C, preferably 35°C to 50°C, for 12 hours to 48 hours, preferably 16 hours to 24 hours. It may be performed during, but is not limited to.

In one embodiment of the present invention, the fermentation of step (2) may be performed 1 to 3 times.

In one embodiment of the present invention, step (2) may further include a step of aging after fermentation. The aging is preferably performed for 1 to 3 days through a convective heat circulation method at 40°C to 50°C and wet heating using convection heat at a humidity of 40% to 60%, but is not limited thereto.

In one embodiment of the present invention, in the manufacturing method of the present invention, (3) concentrating the fermentation product of step (2) to obtain a fermentation concentrate, It may further comprise the step of recovering the by-product and drying it.

In one embodiment of the present invention, the fermentation product of step (2) includes a liquid phase and a solid phase, and in step (3), the liquid portion becomes a fermentation concentrate through freeze drying or vacuum drying, The solid portion may be the remaining by-products except for the fermentation concentrate among the fermentation products. The by-product may be separately recovered, dried at room temperature or hot air, and the dried by-product may be pulverized to prepare a powder.

In one embodiment of the present invention, the concentration of the fermentation concentrate in step (3) is 10 to 30 brix, preferably 15 to 25 brix, more preferably 17 to 23 brix, even more preferably 18 to 22 brix, but is not limited thereto.

In one embodiment of the present invention, in the manufacturing method of the present invention, (4) mixing the fermentation concentrate obtained in step (3) and the dry by-product with an additive, kneading in a kneader, and from the kneading product It may further comprise the step of preparing the formulation. At this time, the description of the additive is the same as the additional ingredients or additives other than the fermented product of the oriental medicine composite material, as described above in the food composition for preventing or improving obesity of the present invention.

In one embodiment of the present invention, in step (4), the fermentation concentrate, the dried by-product, and the additive together with the rice bran fermented product may be further mixed. In this case, the ratio of the total weight of the fermentation concentrate and the dry by-product to the fermented rice bran by weight may be 1:1 to 5:1, preferably 3:1 to 5:1. By adjusting their weight ratio within the above range, it is possible to reduce the amount of the excipient while greatly improving the anti-obesity effect.

In one embodiment of the present invention, the fermented rice bran may be fermented rice bran using a culture medium of lactic acid bacteria. At this time, the description of the lactic acid bacteria culture is the same as described above in the pharmaceutical composition for preventing or treating obesity of the present invention.

In one embodiment of the present invention, the fermented rice bran may be prepared by a manufacturing method comprising the following steps, but is not limited thereto:

1) preparing a mixture by mixing rice bran and water;

2) preparing a gelatinized rice bran mixture by heating the mixture to gelatinize rice bran;

3) adding a lactic acid bacteria culture solution to the luxurious rice bran mixture; and

4) preparing a fermented rice bran by fermenting the luxurious rice bran mixture to which the lactic acid bacteria culture is added.

In one embodiment of the present invention, step 1) may be performed by mixing 100 to 200 parts by weight of water per 100 parts by weight of rice bran. In this case, the rice bran may be in the form of rice bran powder obtained by pulverizing the raw rice bran using a grinder, but is not limited thereto.

In one embodiment of the present invention, in the gelatinization of step 2), the mixture obtained in step 1) is subjected to a temperature condition of 100° C. to 140° C. and a pressure condition of 0.9 atm to 1.5 atm for 1 hour to 5 hours, preferably Preferably, it can be carried out by heating for 2 to 4 hours.

The step 2) is a step of gelatinizing rice bran, and “gelatinization” means that when starch is heated in water or treated with a solvent such as an alkali solution, it expands by heat and moisture so that its physicochemical properties and structure are changed. It refers to the process of changing to have properties such as viscosity increase, water solubility increase or volume increase, or a phenomenon in which the whole becomes translucent and almost uniform colloidal material, also called gelatinization.

In one embodiment of the present invention, step 2) may include the step of cooling the gelatinized rice bran mixture to a temperature range of 30° C. to 50° C., preferably 35° C. to 45° C. after gelatinizing the rice bran.

In one embodiment of the present invention, in step 4), the gelatinized rice bran mixture to which the lactic acid bacteria culture is added is heated at a temperature of 30° C. to 50° C., preferably 35° C. to 45° C., for 12 hours to 48 hours, preferably may be performed by fermentation for 16 hours to 24 hours, but is not limited thereto.

In one embodiment of the present invention, the method for producing a fermented rice bran may further include 5) drying the fermented rice bran obtained in step 4) and pulverizing it to prepare a powder.

The drying step is i) natural drying at room temperature for 10 hours to 60 hours, ii) hot air drying at a temperature condition of 30°C to 60°C for 1 hour to 40 hours, or iii) -50°C to -80°C It can be carried out by freeze-drying for 20 to 100 hours at a temperature condition of

Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in various different forms, and the examples described herein are only for illustrating the present invention, and the present invention is not limited to the following examples.

<Production of fermented rice bran>

Preparation Example 1: Preparation of fermented rice bran

Preparation Example 1-1: Preparation of rice bran mixture and luxurious rice bran mixture

After milling the rice bran obtained during the rice milling process into a powder having a size of 450 μm using a grinder, 150 g of tertiary distilled water was added to 100 g of the obtained rice bran powder to prepare a rice bran mixture. Thereafter, the rice bran mixture was steamed for 2-3 hours at a temperature of 100° C. and a pressure of 1.1 atm using a steamer to make the rice bran gelatinous. The gelatinized rice bran mixture was cooled to 37°C to 40°C and used as a rice bran fermentation target.

Preparation Example 1-2: Preparation of lactic acid bacteria culture solution

One, Bifidobacterium breve (Bifidobacterium breve) and Bifidobacterium Infante tooth (Bifidobacterium infantis) Bifidobacterium concentrated powder ^{(1.0 x 10 7 CFU / g} ) in sterile water to 2g 100 containing purchased from GC Green Cross ㎖ was added, and after mixing homogeneously, 900 ㎖ of sterile water was added thereto to obtain 1,000 ㎖ of lactic acid bacteria culture solution.

Preparation Example 1-3: Preparation of fermented rice bran

The lactic acid bacteria culture solution obtained in Preparation Example 1-2 was inoculated into the luxurious rice bran mixture obtained in Preparation Example 1-1 at 2% (v/v), thoroughly mixed using a sterile glass rod, and then completely sealed. Fermented rice bran was prepared by fermentation at 37° C. for 24 hours. After the fermented rice bran was naturally dried at room temperature for 10 hours, it was pulverized to obtain a powder of the fermented rice bran.

<Production of fermented product of oriental medicine composite material>

Example 1: Preparation of fermented product of oriental medicine composite material containing three vegetables and black garlic

Aspergillus niger and Saccharomyces cerevisiae purchased from Barun F&B 2 g of complex yeast concentrated powder (1.0×10 ⁹ CFU/g) containing 100 ml of sterile water After mixing homogeneously, 900 ml of sterile water was further added thereto to obtain 1,000 ml of yeast culture solution.

After drying 10 g of oriental medicine composite material containing three vegetables 1.5 g, black garlic 1.5 g, green tea 1.0 g, dermis 1.0 g, angelica 1.0 g, turmeric 0.8 g, gardenia 0.8 g, astragalus 0.8 g, crust 0.8 g, and health 0.8 g By pulverization, an herbal composite material powder was obtained.

10 g of the oriental medicine composite material powder was placed in a fermentation tray, and 250 ml of the yeast culture medium was put and immersed, then put into a fermenter and fermented at 37° C. for 24 hours to prepare a fermented product of the oriental medicine composite material.

The fermented product of the oriental medicine composite material contained a liquid phase and a solid phase, and the fermented product of the oriental medicine composite material was concentrated at 40° C. for 4 hours using a vacuum rotary concentrator to obtain a fermentation concentrate. The by-products (solid form) except for the fermentation concentrate were recovered from the fermentation product and dried with hot air at 60° C. for 72 hours to obtain a dried by-product. After the dried by-product was pulverized into a powder having a size of 450 μm, fermentation by-product powder was obtained. At this time, the concentration of the fermentation concentrate was 18 to 22 brix.

By mixing 2.5 g of the fermentation concentrate obtained above and 1.5 g of the fermentation by-product powder, 4.0 g of a sample of fermented oriental medicine composite material was prepared.

Example 2: Preparation of a mixture of fermented product of oriental medicine composite material and fermented rice bran

1.0 g of the fermented rice bran powder obtained in Preparation Example 1 was mixed with 4.0 g of the fermented product sample of the oriental medicine composite material obtained in Example 1 to prepare 5.0 g of a mixture sample of the fermented product of the oriental medicine composite material and rice bran fermented product .

Comparative Example 1: Preparation of three fermented vegetables

Aspergillus niger and Saccharomyces cerevisiae purchased from Barun F&B 2 g of complex yeast concentrated powder (1.0×10 ⁹ CFU/g) containing 100 ml of sterile water After mixing homogeneously, 900 ml of sterile water was further added thereto to obtain 1,000 ml of yeast culture solution.

After drying 10 g of Samchae, it was pulverized to obtain Samchae powder.

10 g of the samchae powder was placed in a tray for fermentation, 250 ml of the yeast culture solution was put and immersed, and this was put into a fermenter and fermented at 37° C. for 24 hours to prepare fermented samchae.

The fermented Samchae contained a liquid phase and a solid phase, and the fermented Samchae was concentrated at 40° C. for 4 hours using a vacuum rotary concentrator to obtain a fermentation concentrate, and by-products (solid phase) form) was recovered and dried with hot air at 60° C. for 72 hours to obtain a dried by-product, and after the dried by-product was pulverized into a powder having a size of 450 μm, a powder of a fermentation by-product was obtained. At this time, the concentration of the fermentation concentrate was 18 to 22 brix.

By mixing 2.5 g of the above-obtained fermentation concentrate and 1.5 g of the fermentation by-product powder, 4.0 g of fermented three vegetables were prepared.

Experimental Example 1: Confirmation of cytotoxicity using the ferment mixture sample of Example 2

The cytotoxicity of 3T3-L1 adipocytes (predipocytes) by the sample of the mixture of the fermented product of the oriental medicine composite material and the fermented rice bran obtained in Example 2 was confirmed.

Specifically, 3T3-L1 preadipocyte 1 x 10 ⁵ cells were dispensed into a 24-well tissue culture plate and adhered for 24 hours, and then the mixture sample obtained in Example 2 was treated by concentration (i.e. Sample untreated, 50 μg/ml treatment, 100 μg/ml treatment, 150 μg/ml treatment, 200 μg/ml treatment, 300 μg/ml treatment, 400 μg/ml treatment and 500 μg/ml treatment) were cultured for 72 hours . After the sample treatment, the medium containing the WST reagent was replaced and reacted for 1 hour, and then the absorbance at 450 nm was measured for each medium using a multi-plate reader, and cell viability of 3T3-L1 preadipocytes was analyzed. .

1, when the cell viability of the untreated mixture sample obtained in Example 2 (sample concentration of 0 μg/ml) is 100%, the mixture sample obtained in Example 2 When treated at a concentration of 50 μg/ml to 300 μg/ml, the cell viability was 100% or more, and almost no cytotoxicity was induced, and the cell viability was very high even when treated at a concentration of 500 μg/ml It was confirmed that the mixture sample obtained in Example 2 was a material without cytotoxicity.

Experimental Example 2: Evaluation of pancreatic lipase activity inhibition

Experimental Example 2-1: Evaluation of the ability to inhibit lipase activity using the oriental herbal composite material powder before fermentation of Example 1

The ability to inhibit pancreatic lipase enzyme activity of the oriental herbal composite material obtained in Example 1 before fermentation was confirmed.

Specifically, a substrate composed of 0.25 M Tris (pH 7.7), 250 mM CaCl2, and 5 mM 4-nitrophenyldodecanoate (PNPD) was put in a 1.5ml tube, mixed well, and then heated at 37°C. It was preheated for 5 minutes. After that, 0.25 μg of lipase dissolved in 0.25 M Tris (pH 7.7) and 0.25 mg of the oriental herbal composite material obtained in Example 1 before fermentation were added to the tube, and then reacted at 37° C. for 10 minutes, followed by 20% Sodium dodecyl sulfate (SDS) was added, and the reaction was terminated.

After completion of the reaction, the reaction product was centrifuged at a temperature of 4° C. at a speed of 15,000 rpm for 20 minutes, and the separated supernatant was dispensed in a 96-well tissue culture plate and absorbance at 412 nm using a multi-plate reader was measured. measured. After reacting for 10 minutes, a value obtained by subtracting the absorbance of the sample before the reaction from the absorbance of the sample was expressed as a percentage compared to the absorbance of the sample before the reaction.

Experimental Example 2-2: Evaluation of the ability to inhibit lipase activity using the fermented product sample of the oriental medicinal composite material of Example 1

The ability to inhibit lipase activity was evaluated in the same manner as in Experimental Example 2-1, except that 0.25 mg of the fermented product sample of the oriental medicine composite material obtained in Example 1 was used instead of the oriental medicine composite material before fermentation of Example 1.

Experimental Example 2-3: Evaluation of the ability to inhibit lipase activity using the fermentation mixture sample of Example 2

Lipase activity was carried out in the same manner as in Experimental Example 2-1, except that 0.25 mg of a mixture sample of the fermented product of the oriental medicinal composite obtained in Example 2 and the fermented rice bran was used instead of the oriental medicinal composite material before fermentation of Example 1 The inhibitory ability was evaluated.

Experimental Example 2-4: Evaluation of the ability to inhibit lipase activity using ginseng powder before fermentation of Comparative Example 1

The ability to inhibit lipase activity was evaluated in the same manner as in Experimental Example 2-1, except that 0.25 mg of the ginseng powder obtained in Comparative Example 1 was used instead of the oriental herbal composite material before fermentation of Example 1.

Experimental Example 2-5: Evaluation of the ability to inhibit lipase activity using the three fermented samples of Comparative Example 1

The ability of inhibiting lipase activity was evaluated in the same manner as in Experimental Example 2-1, except that 0.25 mg of the fermented three vegetables sample obtained in Comparative Example 1 was used instead of the oriental herbal composite material before fermentation of Example 1.

The ability to inhibit each lipase enzyme activity measured in Experimental Examples 2-1 to 2-5 is shown in Table 1 below.

division Lipase Relative Activity (%) Lipase relative activity inhibition (%) Untreated lipase activity 100 0 Experimental Example 2-1 (Oriental medicine composite material powder before fermentation) 74.5 25.5 Experimental Example 2-2 (Fermented product sample of oriental medicine composite material) 9.8 90.2 Experimental Example 2-3 (Fermented product of oriental medicine composite material and
Mixture sample of fermented rice bran) 1.1 98.9 Experimental Example 2-4 (three vegetables powder before fermentation) 98.8 1.2 Experimental Example 2-5 (fermented three vegetables sample) 48.7 51.3

As shown in Table 1, the lipase enzyme activity inhibition of Experimental Example 2-4 using unfermented ginseng powder as a sample was 1.2%, and there was almost no effect of inhibiting lipase enzyme activity. Experimental Example 2 using fermented ginseng powder as a sample The degree of inhibition of lipase enzyme activity of -5 was 51.3%, which inhibited the enzyme activity of lipase by half.

The inhibition of lipase enzyme activity in Experimental Example 2-1 using an unfermented oriental medicinal composite material as a sample was low at 25.5%, but the lipase enzyme activity inhibition in Experimental Example 2-2 using a fermented oriental medicinal composite material as a sample was 90.2 %, and the inhibition of lipase enzyme activity in Experimental Example 2-3 using a mixture of fermented product of oriental medicine composite material and fermented rice bran as a sample was 98.9%, suggesting that lipase enzyme activity was almost eliminated.

As can be seen above, the fermented product of the oriental medicine composite material according to the present invention exhibited an effect of inhibiting lipase enzyme activity that was about 1.76 times greater than that of the fermented three vegetables, and the fermented product of the oriental medicine composite material according to the present invention The mixture exhibited an effect of inhibiting lipase enzyme activity that was about 1.93 times greater than that of three fermented vegetables.

When food is ingested, the fat contained in food is decomposed into fatty acids and monoglycerides by the action of lipase enzymes, and the absorbed fatty acids are resynthesized into triglycerides in the epithelial cells of the small intestine and enter the blood into the liver, adipose tissue, and muscle. is sent to The remaining triglycerides are accumulated in each tissue, and when fat accumulation is excessive, obesity occurs. Therefore, when the enzymatic activity of lipase is inhibited, digestion and absorption of fat in ingested food are inhibited, thereby excreting fat, thereby preventing the accumulation of fat in the body.

Experimental Example 3: Evaluation of the ability of preadipocytes to inhibit differentiation into adipocytes

The ability to inhibit the differentiation of 3T3-L1 preadipocytes into adipocytes was confirmed by the mixture sample of the fermented product of the oriental medicine composite material obtained in Example 2 and the fermented rice bran. Differentiation of 3T3-L1 adipocytes into adipocytes was induced through MDI treatment.

^{Specifically, 2×10 5} 3T3-L1 adipocytes per well were dispensed in a 12-well tissue culture plate and replaced with DEME medium containing 10% fetal bovine serum (FBS) and penicillin/streptomycin after 2 days. did After 2 days, the mixture sample obtained in Example 2 was treated by concentration while replacing it with the MDI treatment medium (ie, 50 μg/ml treatment, 100 μg/ml treatment, 150 μg/ml treatment, and 200 μg/ml treatment) treatment), and MDI-treated samples (insulin, DEX and IBMX) were treated a total of 4 times at 2-day intervals. Two days after the fourth MDI sample treatment, the activity of adipogenesis into adipocytes and the inhibition of adipogenesis into adipogenesis by the mixture sample obtained in Example 2 were measured using a phase-contrast microscope at 200 Observation was taken at magnification, and at this time, inhibition of adipogenesis was analyzed through Oil Red O staining.

Through MDI treatment, 3T3-L1 preadipocytes are differentiated into adipocytes. The more adipogenesis occurs, the more adipocytes containing fat, and the more fat is stained red. will be visible

As shown in the accompanying FIG. 2, as the concentration of the mixture sample of the fermented product obtained in Example 2 increases, it can be seen that the size and number of fat parts dyed in red gradually decrease. This indicates that the higher the treatment concentration of the mixture sample of the fermented product obtained in Example 2, the more active the inhibition of adipogenesis (adipogenesis).

2, “Con” indicates 3T3-L1 adipose progenitor cell medium that is not treated with MDI and the mixture sample obtained in Example 2, and “0” indicates the MDI-treated, but obtained in Example 2 3T3-L1 adipocyte progenitor cell medium without mixture sample indicates 3T3-L1 adipocyte progenitor medium, where “50” to “200” are MDI-treated and 3T3-L1 adipocyte progenitor cell medium treated with the mixture sample obtained in Example 2 according to concentration indicates

Experimental Example 4: Evaluation of triglyceride production inhibitory ability

The ability to inhibit fat (triglyceride) production by a mixture sample of the fermented product of the oriental medicine composite material obtained in Example 2 and the fermented rice bran was confirmed.

Specifically, in order to quantitatively evaluate the fat (triglyceride) production inhibitory ability by the treatment of the mixture sample obtained in Example 2, Oil Red was obtained from the adipocyte differentiation medium of Experimental Example 3, as shown in the attached FIG. 2 . Triglyceride content was measured by extracting fats stained in red by O staining, and the results are shown in Table 2 below.

Treatment concentration of the mixture sample of Example 2 (μg/ml) Relative content of triglycerides (%) MDI Untreated and Mixture Sample Untreated Medium 20 MDI-treated and mixed sample untreated media 100 (reference content) MDI treatment and mixture sample 50 μg/ml treatment medium 95 MDI treatment and mixture sample 100 μg/ml treatment medium 86 MDI treatment and mixture sample 150 μg/ml treatment medium 73 MDI treatment and mixture sample 200 μg/ml treatment medium 52

As shown in Table 2 above, when the content of triglyceride of the stained fat extracted from the medium in which the differentiation into adipocytes was normally progressed through MDI treatment was 100%, differentiation into adipocytes in the MDI-untreated medium is not made, the content of the triglyceride of the dyed fat extracted from the medium was only 20%, and even in the MDI-treated medium, the higher the treatment concentration of the mixture sample of the fermented product obtained in Example 2, the more extracted from the medium It can be seen that the triglyceride content of the dyed fat was significantly reduced.

In the medium treated with MID and the mixture sample obtained in Example 2 at a concentration of 200 μg/ml, the triglyceride content of the dyed fat extracted from the medium was reduced by 52%. This means that in the medium in which the mixture sample was treated at a concentration of 200 μg/ml, the differentiation of adipocytes into adipocytes was inhibited by about half (48%).

This indicates that the mixture sample of the fermented product of the oriental medicine composite material and the fermented rice bran obtained in Example 2 can significantly inhibit the differentiation of adipogenesis into adipocytes.

Experimental Example 5: Confirmation of changes in body weight through animal experiments

Experimental Example 5-1: Preparation of experimental animals

As the mice used as experimental animals, 3-week-old male ICR mice were purchased from Daejeon, Korea, and acclimatized for one week before use. The average weight of the ICR mice was 25.85±0.11 g, and at the same time obesity was induced through a high-fat diet (Central Experimental Animal, Korea), the sample obtained in Example 2 was orally administered once daily. Contrast was controlled at 12-hour intervals in the experimental animal breeding room, and the temperature was maintained at 23±2° C., and the humidity was maintained at 50-60%. This animal experiment was conducted in compliance with the Wonkwang University Guide for Animal Experimentation, and was performed with the approval of the Wonkwang University Animal Experimental Ethics Committee (Approval NO. WKU15-10). High-fat feed (Rodent Diet with 60% kcal fat) was purchased from Damul Science (Daejeon, Korea), and the composition of the feed is shown in Table 3 below.

Experimental Example 5-2: Composition of the experimental group

Experimental animals were classified into 4 groups, and the group fed with a normal diet for 6 weeks was treated as a normal group (NC, n=6), and the group fed a high-fat diet as a control group (HFD, n=6) was fed a high-fat diet. and the hyperlipidemia treatment drug Simvastatin 20 mg/kg was administered as the drug administration group (SIM, n = 6), and the mixture of the fermented oriental medicine composite material obtained in Example 2 and the fermented rice bran obtained in Example 2 after eating a high-fat feed The administered group was classified into a fermentation mixture administered group (FC, n=6). For the calculation of the number of animals in a group, the minimum number covering statistical significance was used in accordance with the 3R principle. D.W was administered to the Normal group and Control group, and each sample was orally administered once a day.

Experimental Example 5-3: Confirmation of change in body weight by the formulation obtained in Example 2

While providing the prescribed diet for 6 weeks to the four groups designated in Experimental Example 5-2, the body weight, the amount of food and the amount of drinking water were measured. Specifically, the body weight was measured using a digital meter (IB-3100, Innotem, Yangju) at a fixed time (AM. Measurements were made at a constant time (AM. 10 o'clock). Food Efficiency Ratio (FER) was converted by dividing the weight gain during the trial period by the food intake during the same period.

Table 4 below shows the results of body weight, weight gain, food intake and dietary efficiency through animal experiments for 6 weeks.

measurement experimental group Normal group (NC) Control (HFD) Drug administration group (SIM) Formulation administration group (FC) Initial weight (g) 25.68 26.38 26.10 25.82 final weight (g) 34.3. 38.67 37.12 36.54 Food amount (g/week) 22.58 20.25 18.41 17.98 Water volume (ml/week) 25.40 24.15 20.21 19.82 Weight gain (g/week) 1.23 1.76 1.57 1.53 PER 0.03 0.05 0.05 0.05

As shown in Table 4, the average body weight at the start of the high-fat diet was 25.68 to 26.38 g, showing no significant difference. However, after 6 weeks, the normal group (NC group) increased 33.5%, the control group (HFD group) increased to 46.6%, the drug administration group (SIM group) increased 42.2%, and the In 41.5% of cases, the weight gain was lower than that of the drug-administered group (SIM group). These results can confirm that the weight loss effect was uniquely greater than that of the drug control group (SIM group) in a situation where the dietary intake was similar to that of the rest of the groups except for the normal group (NC group).

Among the control group, drug-administered group, and fermentation mixture-administered group that were treated with a high-fat diet for 6 weeks, the weight gain in the control group without drug administration and fermentation mixture administration was 46.6%, whereas in the drug-administered group and fermentation mixture administration group, the weight gain was 42.2%, respectively. And it was possible to confirm the anti-obesity effect by reducing the weight gain relatively to 41.5%, and in particular, the ferment mixture sample obtained in Example 2 of the present invention was administered rather than the drug administration group administered with Simvastatin 20 mg/kg, a hyperlipidemia treatment drug. It shows that the anti-obesity effect of the group administered with the fermentation mixture is superior.

Experimental Example 6: Nitric oxide (NO) production inhibitory ability evaluation

Experimental Example 6-1: Nitric oxide (NO) production inhibitory ability evaluation using the fermented product sample of the oriental medicinal composite material of Example 1

The anti-inflammatory activity (immunity index) was confirmed through the evaluation of the nitric oxide (NO) production inhibitory ability of the fermented product sample of the oriental medicine composite material obtained in Example 1.

Specifically, the RAW 264.7 cell line, a murine macrophage cell line, was cultured in DMEM medium containing 10% fetal bovine serum (FBS) and penicillin/streptomycin at a temperature of 37° C. and 5% CO _² conditions. Thereafter, 3.0 × 10 per well were dispensed and attached to a 24-well tissue culture plate, and then nitric oxide (NO) production was induced by treatment with 1 μg/ml LPS (lipopolysaccharides), and the oriental medicine complex obtained in Example 1 After processing the fermented material samples by concentration (ie, 50 μg/ml treatment, 100 μg/ml treatment, 150 μg/ml treatment, and 200 μg/ml treatment), the amount of nitric oxide (NO) production was measured through the Griess reagent system. By measuring, the ability to inhibit nitric oxide (NO) production was analyzed. At this time, the amount of nitrogen monoxide (NO) production was expressed as an average value of three repeated measurements.

Experimental Example 6-2: Nitric oxide (NO) production inhibitory ability evaluation using three fermented samples of Comparative Example 1

In Comparative Example 1 instead of treating the fermented product sample of the oriental medicine composite material obtained in Example 1 by concentration (ie, 50 μg/ml treatment, 100 μg/ml treatment, 150 μg/ml treatment, and 200 μg/ml treatment) In the same manner as in Experimental Example 6-1, except that the obtained three fermented three samples were treated by concentration (ie, 50 μg/ml treatment, 100 μg/ml treatment, 150 μg/ml treatment, and 200 μg/ml treatment). The ability to inhibit nitric oxide (NO) production was analyzed.

Each of the nitric oxide (NO) production inhibitory ability measured in Experimental Examples 6-1 and 6-2 is shown in Table 5 below.

division Concentration of fermented oriental medicine composite material sample (μg/ml) Concentration of three fermented samples (μg/ml) 0 50 100 150 200 0 50 100 150 200 NO (μM) 50.1 38.4 25.3 18.7 12.2 50.2 48.3 45.8 40.2 37.7

Macrophages, one of the cells involved in the immune response in the body, play an important role in the inflammatory response. Macrophages are activated by exposure to stimuli such as pro-inflammatory cytokines and lipopolysaccharides (LPS), which are components of the outer membrane of Gram-negative bacteria. When macrophages are activated, they release inflammatory cytokines and induce the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) to form nitric oxide (NO) and prostaglandin E2 (PGE2) The inflammatory response is mediated by the production of the same inflammatory factor. In this process, nitric oxide (NO) produced excessively by iNOS not only causes inflammation and tissue damage by itself, but also converts to a more reactive form when combined with active oxygen to cause necrosis of living tissue. can Therefore, inhibiting the production of nitric oxide (NO) means that it has anti-inflammatory activity, which means that it has an immune-enhancing effect.

Activation of the RAW 264.7 cell line by treatment with LPS can induce nitric oxide (NO) production.

As shown in Table 5 above, the amount of NO production in the medium in which the fermented product sample of the oriental medicinal composite material of Example 1 according to the present invention was not treated was 50.1 μM, but the fermented product sample treatment concentration of the oriental medicinal composite material of Example 1 according to the present invention was As it increases, it can be seen that the amount of NO production in the medium was significantly reduced.

The amount of NO production in the medium in which the fermented product sample of the oriental medicine composite material obtained in Example 1 was treated at a concentration of 200 μg/ml was 12.2 μM, and in the medium in which the fermented product sample of the oriental medicine composite material of Example 1 was not treated It was reduced by about 24% compared to the amount of NO produced. This means that NO production was suppressed by about 76% in the medium in which the fermented product sample of the oriental medicine composite material was treated at a concentration of 200 μg/ml.

This indicates that the fermented product sample of the oriental medicine composite material obtained in Example 1 significantly inhibits NO production induced by activated macrophages, thereby exhibiting excellent anti-inflammatory activity.

On the other hand, even in the case of the fermented ginseng sample obtained in Comparative Example 1, the amount of NO production in the medium decreased as the treatment concentration increased. The amount of NO production in was 37.7 μM, which was reduced by about 75% compared to the amount of NO production in the medium untreated in the fermented ginseng sample of Comparative Example 1, which was found in the medium in which the fermented ginseng sample was treated at a concentration of 200 μg/ml. It means that the production was suppressed by about 25%.

From this, it can be seen that the fermented product sample of the oriental medicine composite material of Example 1 according to the present invention exhibits an NO production inhibitory effect three times or more compared to the fermented three vegetables sample of Comparative Example 1, and thus it can be seen that the anti-inflammatory effect is excellent.

Claims (24)

Fermented product of oriental medicine composite material including ginseng, black garlic, green tea, dermis, angelica, turmeric, gardenia, astragalus, crust and health; and rice bran fermented product as an active ingredient,
The total content of the three vegetables and black garlic is 30 to 60 parts by weight based on 100 parts by weight of the total of the herbal composite material,
The weight ratio of the fermented product of the oriental medicine composite material and the fermented rice bran is 3:1 to 5:1,
A pharmaceutical composition for preventing or treating obesity. delete delete According to claim 1, wherein the fermented product of the oriental medicine composite material, Aspergillus niger (Aspergillus niger), Aspergillus oryzae (Aspergillus oryzae), Saccharomyces cerevisiae (Saccharomyces cerevisiae) or their A pharmaceutical composition for preventing or treating obesity, wherein the oriental medicine composite material is fermented using a yeast culture medium obtained by culturing a yeast strain selected from the group consisting of combinations. delete The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the fermented rice bran is fermented rice bran using a lactic acid bacteria culture medium. delete (1) preparing a yeast culture solution;
(2) fermenting the yeast culture medium obtained in step (1) by adding oriental herbal composite materials including ginseng, black garlic, green tea, dermis, angelica, turmeric, gardenia, astragalus, crust and health;
(3) concentrating the fermentation product of step (2) to obtain a fermentation concentrate, and recovering and drying by-products other than the fermentation concentrate from the fermentation product of step (2); and
(4) mixing the fermentation concentrate and the dry by-product obtained in step (3) with an excipient or diluent together with the rice bran fermented product, kneading in a kneader, and preparing a formulation from the kneaded product do,
The total content of the three vegetables and black garlic is 30 to 60 parts by weight based on 100 parts by weight of the total of the herbal composite material,
The total weight of the fermentation concentrate and the dry by-product and the weight ratio of the rice bran fermented product are 3:1 to 5:1,
Method for preparing a pharmaceutical composition for preventing or treating obesity. The method of claim 8, wherein the yeast culture medium of step (1), Aspergillus niger (Aspergillus niger), Aspergillus oryzae (Aspergillus oryzae), Saccharomyces cerevisiae (Saccharomyces cerevisiae) or these A method for producing a pharmaceutical composition for preventing or treating obesity, which is prepared by culturing a yeast strain selected from the group consisting of a combination of delete delete delete delete delete Fermented product of oriental medicine composite material including ginseng, black garlic, green tea, dermis, angelica, turmeric, gardenia, astragalus, crust and health; and rice bran fermented product as an active ingredient,
The total content of the three vegetables and black garlic is 30 to 60 parts by weight based on 100 parts by weight of the total of the herbal composite material,
The weight ratio of the fermented product of the oriental medicine composite material and the fermented rice bran is 3:1 to 5:1,
A food composition for preventing or improving obesity. delete delete The method of claim 15, wherein the fermented product of the oriental medicine composite material, Aspergillus niger (Aspergillus niger), Aspergillus oryzae (Aspergillus oryzae), Saccharomyces cerevisiae (Saccharomyces cerevisiae) or their A food composition for preventing or improving obesity, wherein the oriental medicine composite material is fermented using a yeast culture solution obtained by culturing a yeast strain selected from the group consisting of combinations. delete The food composition for preventing or improving obesity according to claim 15, wherein the fermented rice bran is fermented rice bran using a culture medium of lactic acid bacteria. delete The food composition for preventing or improving obesity according to claim 15, wherein the food composition for preventing or improving obesity is a health functional food. (1) preparing a yeast culture solution;
(2) fermenting the yeast culture medium obtained in step (1) by adding oriental herbal composite materials including ginseng, black garlic, green tea, dermis, angelica, turmeric, gardenia, astragalus, crust and health;
(3) concentrating the fermentation product of step (2) to obtain a fermentation concentrate, and recovering and drying by-products other than the fermentation concentrate from the fermentation product of step (2); and
(4) mixing the fermentation concentrate and the dry by-product obtained in step (3) with an additive together with the rice bran fermented product, kneading in a kneader, and preparing a formulation from the kneaded product,
The total content of the three vegetables and black garlic is 30 to 60 parts by weight based on 100 parts by weight of the total of the herbal composite material,
The total weight of the fermentation concentrate and the dry by-product and the weight ratio of the rice bran fermented product are 3:1 to 5:1,
Method for producing a food composition for preventing or improving obesity. The method of claim 23, wherein the yeast culture medium of step (1), Aspergillus niger (Aspergillus niger), Aspergillus oryzae (Aspergillus oryzae), Saccharomyces cerevisiae (Saccharomyces cerevisiae) or these A method for producing a food composition for preventing or improving obesity, which is prepared by culturing a yeast strain selected from the group consisting of a combination of.

Images